HLS Therapeutics Inc (74D) Stock Statistics & Valuation Metrics
Total Valuation
HLS Therapeutics Inc has a market cap or net worth of EUR 89.09M. The enterprise value is EUR 177.89M.
- Market Cap
- EUR 89.09M
- Enterprise Value
- EUR 177.89M
Share Statistics
HLS Therapeutics Inc has 30,935,060 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 30,935,060
- Owned by Insiders
- 0.11%
- Owned by Institutions
- 1.65%
Financial Efficiency
HLS Therapeutics Inc’s return on equity (ROE) is -0.21 and return on invested capital (ROIC) is -3.48%.
- Return on Equity (ROE)
- -0.21
- Return on Assets (ROA)
- -0.09
- Return on Invested Capital (ROIC)
- -3.48%
- Return on Capital Employed (ROCE)
- -0.04
- Revenue Per Employee
- 664.37K
- Profits Per Employee
- -148.80K
- Employee Count
- 85
- Asset Turnover
- 0.41
- Inventory Turnover
- 4.00
Valuation Ratios
The current PE Ratio of HLS Therapeutics Inc is -12.23. HLS Therapeutics Inc’s PEG ratio is -0.20.
- PE Ratio
- -12.23
- PS Ratio
- 1.79
- PB Ratio
- 2.00
- Price to FCF
- 5.67
- Price to Operating Cash Flow
- 6.11
- PEG Ratio
- -0.20
Income Statement
In the last 12 months, HLS Therapeutics Inc had revenue of 56.47M and earned -12.65M in profits. Earnings per share was -0.40.
- Revenue
- 56.47M
- Gross Profit
- 24.01M
- Operating Income
- ―
- Pretax Income
- -13.10M
- Net Income
- -12.65M
- EBITDA
- 18.02M
- Earnings Per Share (EPS)
- -0.40
Cash Flow
In the last 12 months, operating cash flow was 18.13M and capital expenditures -695,453, giving a free cash flow of 17.43M billion.
- Operating Cash Flow
- 18.13M
- Free Cash Flow
- 17.43M
- Free Cash Flow per Share
- 0.52
Dividends & Yields
HLS Therapeutics Inc pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 17.63%
- Earnings Yield
- -7.75%
Stock Price Statistics
- Beta
- 0.04
- 52-Week Price Change
- -14.72%
- 50-Day Moving Average
- 2.35
- 200-Day Moving Average
- 2.51
- Relative Strength Index (RSI)
- 63.88
- Average Volume (3m)
- ―
Important Dates
HLS Therapeutics Inc upcoming earnings date is Nov 12, 2026, Before Open (Not Confirmed).
- Last Earnings Date
- Aug 12, 2026
- Next Earnings Date
- Nov 12, 2026
- Ex-Dividend Date
- ―
Financial Position
HLS Therapeutics Inc as a current ratio of 1.11, with Debt / Equity ratio of 80.79%
- Current Ratio
- 1.11
- Quick Ratio
- 0.80
- Debt to Market Cap
- 0.44
- Net Debt to EBITDA
- 2.11
- Interest Coverage Ratio
- -0.58
Taxes
In the past 12 months, HLS Therapeutics Inc has paid -452.79K in taxes.
- Income Tax
- -452.79K
- Effective Tax Rate
- 0.03
Enterprise Valuation
HLS Therapeutics Inc EV to EBITDA ratio is 7.01, with an EV/FCF ratio of 7.26.
- EV to Sales
- 2.29
- EV to EBITDA
- 7.01
- EV to Free Cash Flow
- 7.26
- EV to Operating Cash Flow
- 7.11
Balance Sheet
HLS Therapeutics Inc has EUR 13.71M in cash and marketable securities with EUR 41.84M in debt, giving a net cash position of -EUR 28.13M billion.
- Cash & Marketable Securities
- EUR 13.71M
- Total Debt
- EUR 41.84M
- Net Cash
- -EUR 28.13M
- Net Cash Per Share
- -EUR 0.91
- Tangible Book Value Per Share
- -EUR 1.28
Margins
Gross margin is 61.41%, with operating margin of -7.95%, and net profit margin of -15.20%.
- Gross Margin
- 61.41%
- Operating Margin
- -7.95%
- Pretax Margin
- -16.37%
- Net Profit Margin
- -15.20%
- EBITDA Margin
- 32.60%
- EBIT Margin
- -6.56%
Analyst Forecast
The average price target for HLS Therapeutics Inc is EUR 5.28, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 5.28
- Price Target Upside
- 89.87% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 2
- Revenue Growth Forecast
- -7.05%
- EPS Growth Forecast
- 46.36%
Scores
- Smart Score
- 6
- AI Score
- ―